公开(公告)号：US20210205314A1

公开(公告)日：2021-07-08

申请号：US17210874

申请日：2021-03-24

Applicant: KYOTO UNIVERSITY

Inventor： Masatoshi Hagiwara ,  Masahiko Ajiro

IPC: A61K31/52 ,  A61P43/00 ,  A61P11/00 ,  A61K31/428 ,  A61K31/437 ,  A61K31/443 ,  A61K31/4439 ,  A61K31/4709 ,  A61K31/5377 ,  A61K31/55

Abstract: A pharmaceutical composition for genetic diseases caused by an aberrant splicing regulation is provided. Provided are a pharmaceutical composition for preventing, ameliorating, suppressing progression of, and/or treating the genetic diseases caused by an aberrant splicing regulation, the pharmaceutical composition containing, as an active ingredient, a compound capable of suppressing an aberrant splicing regulation that contributes to the development or progression of genetic diseases caused by an aberrant splicing regulation, and a method for preventing, ameliorating, suppressing progression of, and/or treating the genetic diseases using a compound capable of suppressing an aberrant splicing regulation that contributes to the development or progression of genetic diseases caused by an aberrant splicing regulation.

公开(公告)号：US12138253B2

公开(公告)日：2024-11-12

申请号：US17024435

申请日：2020-09-17

Applicant: Kyoto University

Inventor： Masatoshi Hagiwara ,  Masahiko Ajiro ,  Tetsunori Sakamoto

IPC: A61K31/4409 ,  A61P35/00

Abstract: Provided is a method for preventing, ameliorating, suppressing the progression of, and/or treating a tumor caused by a tumor virus, the method including the step of administering, to a subject, an effective amount of a component that targets a gene product of the tumor virus.

公开(公告)号：US20220226341A1

公开(公告)日：2022-07-21

申请号：US17613303

申请日：2020-05-22

Applicant: Kyoto University

Inventor： Masatoshi Hagiwara ,  Masahiko Ajiro

IPC: A61K31/55 ,  A61K31/4545 ,  A61K31/505 ,  A61K9/00 ,  A61P31/12

Abstract: A novel pharmaceutical composition and method that enable the treatment, amelioration, prevention, and/or suppression of progression of Alzheimer's disease are provided.
Provided is a pharmaceutical composition for preventing, treating, suppressing the progression of, and/or ameliorating Alzheimer's disease, the pharmaceutical composition containing, as an active ingredient, a compound that is capable of suppressing the activation or growth of virus in the brain as one of factors that cause the onset or progression of Alzheimer's disease. Also provided is a method for preventing, treating, suppressing the progression of, and/or ameliorating Alzheimer's disease, the method including administering an effective amount of the compound to a subject.

公开(公告)号：US12023338B2

公开(公告)日：2024-07-02

申请号：US17210874

申请日：2021-03-24

Applicant: KYOTO UNIVERSITY

Inventor： Masatoshi Hagiwara ,  Masahiko Ajiro

IPC: A61K31/519 ,  A61K31/428 ,  A61K31/437 ,  A61K31/443 ,  A61K31/4439 ,  A61K31/4709 ,  A61K31/52 ,  A61K31/5377 ,  A61K31/55 ,  A61P11/00 ,  A61P43/00

CPC classification number: A61K31/52 ,  A61K31/428 ,  A61K31/437 ,  A61K31/443 ,  A61K31/4439 ,  A61K31/4709 ,  A61K31/519 ,  A61K31/5377 ,  A61K31/55 ,  A61P11/00 ,  A61P43/00

Abstract: A pharmaceutical composition for genetic diseases caused by an aberrant splicing regulation is provided. Provided are a pharmaceutical composition for preventing, ameliorating, suppressing progression of, and/or treating the genetic diseases caused by an aberrant splicing regulation, the pharmaceutical composition containing, as an active ingredient, a compound capable of suppressing an aberrant splicing regulation that contributes to the development or progression of genetic diseases caused by an aberrant splicing regulation, and a method for preventing, ameliorating, suppressing progression of, and/or treating the genetic diseases using a compound capable of suppressing an aberrant splicing regulation that contributes to the development or progression of genetic diseases caused by an aberrant splicing regulation.